A prospective study of the efficacy and safety of Denosumab for the prevention of osteoporosis in malignant lymphoma patients treated with prednisolone-containing chemotherapy
Not Applicable
- Conditions
- Malignant Lymphoma
- Registration Number
- JPRN-UMIN000012362
- Lead Sponsor
- Department of Medical Oncology and Hematology, Sapporo Medical University, School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Uncontrolled hepatic disease, renal disease, heart disease, lung disease, diabetes mellitus, hypertention and infectious disease Active concomitant malignancy Severe psychiatric disorders Women who are pregnant or in lactation Hypersensitivity to the denosumab Dental therapy during this trial Current hypocalcemia Patient judged inappropriate for this study by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in bone mineral density Change in bone metabolism markers
- Secondary Outcome Measures
Name Time Method Incidence rate of pathological bone fracture Adverse events